Guardant Health Reports $203.5M Revenue in 10-Q

By Tamara Parker • Thursday, May 01 06:05 • Permanent Link

Guardant Health, Inc. has recently released its 10-Q report, providing a detailed insight into the company's financial performance and operations. Guardant Health is a precision oncology company that offers blood and tissue tests, as well as data sets in the United States and internationally. The company's services include precision oncology testing, development services, and an integrated software-based solution designed for clinical and biopharmaceutical customers. Guardant Health was incorporated in 2011 and is headquartered in Palo Alto, California.

In the 10-Q report, Guardant Health reported total revenue of $203.5 million for the three months ended March 31, 2025, compared to $168.5 million for the same period in 2024. The company also incurred net losses of $95.2 million and $115.0 million for the three months ended March 31, 2025, and 2024, respectively. As of March 31, 2025, Guardant Health had cash, cash equivalents, and restricted cash of approximately $803.9 million.

The report also highlighted several factors impacting Guardant Health's performance, including testing volume, pricing, and product and customer mix. The company's revenue and costs are affected by the volume of tests, average selling price per sample, and the mix of products and customers from period to period. Guardant Health also emphasized the importance of achieving broad coverage and reimbursement for its tests from third-party payers, including commercial and government payers, as a significant factor influencing its revenue.

Additionally, Guardant Health's revenue depends on its relationships with biopharmaceutical customers and its investment in research and development, including the development of new products. The company has made substantial investments in clinical studies to drive physician adoption and favorable coverage decisions by payers. Notably, Guardant Health highlighted the successful launch of its Shield LDT test for colorectal cancer screening, which received FDA approval and became commercially available in the U.S.

Today the company's shares have moved -4.6% to a price of $47.23. For the full picture, make sure to review Guardant Health's 10-Q report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.